معرفی
Paul K Jurasz is an Adjunct Professor in the Faculty of Pharmacy and Pharmaceutical Sciences at the University of Alberta, conducting cutting-edge research on platelet biology and its implications for cardiovascular disease, cancer metastasis, and angiogenesis from his laboratory in the Katz Group Centre for Pharmacy & Health Research.
Education
- BSc, Biological Sciences, University of Alberta, 1998
- PhD, Pharmacology, University of Alberta, 2002
Research Interests
Dr. Jurasz pioneered the discovery of biochemically distinct platelet subpopulations regulated by endothelial nitric oxide synthase (eNOS) signaling pathways. His laboratory investigates how these subpopulations differentially control hemostasis/thrombosis, tumor cell-induced platelet aggregation (TCIPA) in cancer metastasis, and platelet-derived angiogenesis mediators (e.g., VEGF, angiostatin). This work drives development of novel anti-platelet therapies targeting heart attack, stroke, and tumor vascularization while promoting therapeutic angiogenesis for cardiovascular repair.
Publication Trends
Analysis of his 2019-2024 publications reveals dominant themes in platelet heterogeneity (eNOS-negative subpopulations in COVID-19), platelet-cancer cell interactions (prostate cancer stem cells, PD-L1 modulation), and ion channel pharmacology. His work bridges hematology, oncology, and cardiovascular pharmacology with consistent focus on translational applications, appearing in high-impact journals like Journal of Thrombosis and Haemostasis and Thrombosis Research.
Advising and Research Facility
Dr. Jurasz mentors graduate student Aleksandra Franczak in his Katz Group Centre laboratory (Room 3-081), utilizing advanced facilities for platelet function analysis, cancer cell-platelet interaction studies, and angiogenesis modeling. His research program integrates molecular pharmacology, cell biology, and translational approaches to target platelet-mediated pathologies.
